Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Remote ischemic conditioning wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Coronary artery disease wikipedia , lookup
Heart failure wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Rheumatic fever wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Electrocardiography wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
15 Complete Heart Block—Third-Degree Heart Block Mohamad Al-Ahdab Complete atrioventricular (AV) block can be defined as interruption in the transmission of the cardiac impulse from the atria to the ventricles due to an anatomical or functional impairment in the AV conduction system. The conduction disturbance can be transient or permanent. Congenital complete heart block (CHB), the most common and important form in children, was first described in 1901 by Morquio, who also noted a familial occurrence and an association with Stokes-Adams attacks and death. The presence of fetal bradycardia (40– 80 bpm) as a manifestation of CHB was first noted in 1921. The incidence of congenital CHB in the general population varies between 1 in 15,000 to 1 in 22,000 live-born infants. almost all cases presenting in utero or during the neonatal period. Rarely it may explain a few cases occurring later (5% in one report). Other causes include myocarditis and various structural cardiac defects, particularly congenitally corrected transposition of the great arteries, AV discordance, or polysplenia with AV canal defect. Several genetic disorders such as familial atrial septal defect and Kearns-Sayre syndrome (Chapter 18) have been identified (Table 1). In most cases, CHB is characterized pathologically by fibrous tissue that either replaces the AV node and its surrounding tissue or by an interruption between the atrial myocardium and the AV node; other lesions that can occur include congenital absence of the AV node. The net effect is that the block is usually at the level of the AV node. The heart is otherwise structurally normal in these children. ETIOLOGY In the absence of congenital heart disease, neonatal lupus is responsible for 60% to 90% of cases of congenital CHB. Antibodies from a mother with an autoimmune connective tissue disorder, most frequently lupus erythematosus, cross the placenta to the fetus during the first trimester and account for Neonatal Lupus Complete heart block, hepatobiliary disease, malar rash, thrombocytopenia and, less frequently, myocarditis comprise the neonatal lupus primarily presenting in utero or in the neonate. Frequently the only manifestation of neonatal lupus, and by extension an 173 174 COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK TABLE 1. Congenital Complete Heart Block (1 in 20,000 to 25,000 Live Births) No associated structural heart disease Accounts for 67% to 75% of affected infants Immune-mediated complete heart block Accounts for 80% of congenital complete heart block in the absence of structural defect Associated with maternal autoantibodies (anti-SSA/Ro antibodies and anti-SSB/La antibodies) which are the putative etiologic agents Because the mentioned antibodies are of the IgG class, transplacental passage and complete heart block do not appear until after 16 to 20 weeks of gestation High fetal wastage At least 80% of mothers with affected infants will have autoantibodies; most mothers will either have or develop overt symptoms of a systemic connective tissue disorder Discontinuity within the cardiac conduction tissue at level of the atrial axis, within the nodal-ventricular conduction tissue, or within the intraventricular conduction tissue∗ Other associations: (applies to complete heart block at birth as well as letter) Tumors and neoplasia Myocarditis and infections Familial, genetic, and metabolic Long QT syndrome Congestive heart failure occurs but less commonly Fair to good postnatal prognosis Pacemaker in the newborn period indicated by presence of congestive heart failure or a very slow heart rate (<50 to 55 bpm), or at an older age by symptoms Associated with complex structural heart disease Accounts for 25% to 33% of affected infants Most common forms of cardiac malformations: Corrected (I-loop) transposition of the great arteries Single ventricle Defects in atrial and ventricular septation and looping Guarded prognosis: high fetal and newborn mortality (even with pacemaker) Usually with congestive heart failure Early permanent cardiac pacemaker frequently necessary ∗ See Ho et al., Am J Cardiol 1986, 58:291–294. autoimmune abnormality in the mother, is CHB in the newborn. Neonatal lupus is due to transplacental passage of maternal anti-Ro/SSA and/or antiLa/SSB antibodies. Among women with such antibodies, CHB occurs in approximately 2% of pregnancies. Once such a woman has given birth to an infant with CHB, the recurrence rate of CHB in subsequent pregnancies is about 15%; another 6% have an isolated rash consistent with neonatal lupus. Anti-Ro/SSA and/or anti-La/SSB antibodies bind to fetal cardiac tissue, leading to immune-mediated injury to the AV node and its surrounding tissue. Both Ro/SSA and La/SSB antigens are abundant in fetal heart tissue between 18 and 24 weeks. Apoptosis induces translocation of Ro/SSA and La/SSB to the surface of fetal cardiomyocytes; anti- Ro and anti-La antibodies then bind to the surface of the fetal cardiomyocytes and induce the release of tumor necrosis factor by macrophages, resulting in fibrosis. In addition to inducing tissue damage, anti-Ro/SSA and/or anti-La/SSB antibodies inhibit calcium channel activation of the cardiac L- and T-type calcium channels themselves; L-type channels are crucial to action potential propagation and conduction in the AV node. The sinoatrial (SA) node also may be involved; sinus bradycardia has been described in 3.8% percent of fetuses but is usually not permanent. CLINICAL MANIFESTATION The manifestations of CHB vary with the age at presentation. Patients with the 175 COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK neonatal lupus syndrome tend to present earlier than those with CHB not due to neonatal lupus. Presentation in Utero Congenital heart block may present with fetal bradycardia between 18 and 28 weeks of gestation. Almost all of these cases (95% in one series) are due to neonatal lupus, demonstrated by the presence of anti-Ro/SSA and/or anti-La/SSB antibodies in the maternal serum. In utero detection is made by echocardiography, which can estimate the fetal PR interval (Chapter 19). Complications in utero include hydrops fetalis, myocarditis, endocardial fibroelastosis, pericardial effusion, and spontaneous intrauterine fetal death. In one report, among 29 cases diagnosed in utero, there was one therapeutic abortion and six intrauterine fetal deaths; a lower rate of intrauterine death (6 of 87) was seen in another study. Seconddegree block detected in utero can progress to CHB. Infants who present with heart block in utero, but who survive until birth, have a high neonatal mortality rate. In one report, 6 of 22 such infants (27%) died within one week of birth. In another series, 10 of 107 (9%) died within the first three months. Infants born before 34 weeks have a higher mortality rate than those born later (52% vs. 9%). Infants with first- or second-degree heart block at birth can progress to CHB. Presentation in the Neonate As in the fetus, the cardinal finding in CHB in the neonate is a slow heart rate. In addition to bradycardia, other clinical clues in the neonate include intermittent cannon waves in the neck, a first heart sound that varies in intensity, and intermittent gallops and murmurs. As with cases presenting in utero, almost all presenting in the neonatal period (90% in one series) are due to neonatal lupus. The newborn at greatest risk has a rapid atrial rate, often 150 bpm or faster, and a ventricular rate less than 50 bpm. Similar to acquired CHB, the ECG most commonly shows a narrow QRS complex due to a junctional or AV nodal escape or ectopic rhythm (Figure 1). First- or second-degree heart block found in infants at birth can progress to CHB. The outcome for II P I P P P P III V H H V V V HBE H V AVF FIGURE 1. Leads II, I, III, and aVF with a His bundle electrogram (HBE) and ventricular (V) electrogram demonstrating CHB with a His bundle (H) escape rhythm. The ventricular rate is 45 bpm. Reprinted with permission from Ho SY et al. The anatomy of congenital heart block. J Am Cardiol 1986;58(3):292–294 and Elsevier. 176 COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK FIGURE 2. Monitor electrocardiographic tracing in a 10-year-old boy presenting with syncope. The tracing shows intermittent CHB with long pauses. A pacemaker was implanted although his AV conduction improved. Myocarditis was presumed but unproven (negative cardiac biopsy). Reprinted with permission from Ho SY et al. The anatomy of congenital heart block. J Am Cardiol 1986;58(3):292–294 and Elsevier. patients diagnosed as neonates is better than for those diagnosed in utero. In the above cited review, 33 patients presented in the perinatal period; five had signs of heart failure, but none had hydrops fetalis. None died within the first six months, but two died at 0.9 and 1.5 years of age. Our experience has been not as grave. Presentation in Childhood As many as 40% of cases of congenital heart block do not present until childhood (mean age five to six years) (Figure 2). Few of these patients (5%) have neonatal lupus. The diagnosis is usually made when by presentation such as syncope or by detecting a slow pulse. Heart block is confirmed by ECG or by ambulatory ECG monitoring. Complete heart block may be intermittent when first detected, but usually becomes persistent in later childhood. It has been suggested that most unexplained CHB diagnosed for the first time beyond infancy is congenital in origin and has escaped notice because of a higher ventricular rate and the absence of symptoms. However, given that prenatal COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK 177 TABLE 2. Disorders that Can Cause Third-Degree Heart Block Fibrosis and Sclerosis: Fibrosis and sclerosis of the conduction system accounts for about one-half of cases of AV block. Lenegre’s disease has been traditionally used to describe a progressive, fibrotic, sclerodegenerative affliction of the conduction system in younger individuals associated with slow progression to CHB and may be hereditary. Lev’s disease has referred to “sclerosis of the left side of the cardiac skeleton” in older patients, such as that associated with calcific involvement of the aortic and mitral rings. Familial Disease: Familial AV conduction block (Chapter 18). Valvular Disease: Calcification and fibrosis of the aortic or mitral valve rings can extend into the conducting system. Cardiomyopathies: Includes hypertrophic obstructive cardiomyopathy and infiltrative processes such as amyloidosis and sarcoidosis. Hyperthyroidism, myxedema, and thyrotoxic periodic paralysis. Neuromuscular heredodegenerative disease, dermatomyositis, rheumatoid disease, and Paget’s disease. Infections: Myocarditis due to rheumatic fever, diphtheria, viruses, systemic lupus erythematosus, toxoplasmosis, bacterial endocarditis, syphilis, and Lyme disease. Malignancies: Such as Hodgkin’s disease and other lymphomas; multiple myeloma; and cardiac tumors. Drugs: A variety of drugs can impair conduction and cause AV block (Chapter 21). Ischemic heart disease. ultrasound is now well-developed and in wide use, it may be that cases currently missed in fetal life have preserved AV conduction at birth and acquire progressive AV nodal disease thereafter. Consistent with this notion are two observations. First, in a report from one center, the number of childhood case referrals remained constant from 1980 to 1998 despite the introduction of fetal echocardiography and the wide availability of heart rate monitoring during pregnancy and labor. Second, in a series of 102 patients who were asymptomatic through age 15 and were followed for 7 to 30 years thereafter, a slow decline in ventricular rate was noted with increasing age, with a mean heart rate at age 15 of 46 bpm and a mean heart rate after age 40 of 39 bpm. Some patients present with bradycardiarelated symptoms, including reduced exercise tolerance, presyncope, or syncope. Sudden death has also been described. In the above review of 102 patients who were without symptoms through age 15, 27 (26%) had a subsequent syncopal episode, eight of which were fatal. Six of these eight episodes represented a first syncopal episode. Many other disorders can disrupt the AV conduction system (Table 2). These disorders are rare in the young. TREATMENT Management of congenital heart block in utero and in the perinatal period can include steroid therapy if associated with anti-Ro/SSA and anti-La/SSB antibodies, and isoproterenol and/or pacemaker insertion immediately postpartum. The principal therapeutic decision after the immediate perinatal period involves the need for pacemaker placement. Most patients ultimately have a pacemaker inserted, regardless of the time of onset of the syndrome. In one study, by 20 years of age, only 11% of neonatal and 12% of childhood cases had not required pacemaker implantation. In another report that included 40 patients free of symptoms at age 15, pacemakers were required in 90% by age 60 (Chapter 17). The Report of the American College of Cardiology/American Heart Association/ North American Society for Pacing and Electrophysiology Task Force on Practice Guidelines (Committee on Pacemaker Implantation) outlines management of thirddegree AV block in children, adolescents, and patients with congenital heart disease. 178 COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK TABLE 3. Class I Indications for Pacemaker Implant in Children Symptomatic bradycardia (syncope or presyncope) Moderate to marked exercise intolerance Heart failure thought related to the bradycardia Left ventricular dysfunction or low cardiac output A wide QRS escape rhythm or block below the His bundle Complex ventricular arrhythmias In an infant, ventricular rates <50−55 bpm or <70 bpm when associated with congenital heart disease Sustained pause-dependent VT, with or without prolonged QT, in which the efficacy of pacing is thoroughly documented Advanced second- or third-degree AV block persisting at least seven days after cardiac surgery Class I Conditions: Class I conditions are those for which there is evidence and/or general agreement that a permanent pacemaker should be implanted. This class includes patients with advanced second- or third-degree heart block, which is permanent or intermittent (Table 3). These guidelines are reasonable but should be tailored to the patients needs. Infants with CHB but otherwise a normally structural heart may be followed without a pacemaker even if the heart rate is in the 40s when asleep. Equally important is the variation in the heart rate and the overall status of the child. In contrast, an infant with CHB (congenital or surgical) and structural heart disease should receive a pacemaker. Other useful guidelines are outlined in Table 4. Class II Conditions: Class II conditions are those for which permanent pacemakers are TABLE 4. Other Customized Guidelines Cardiac enlargement QT interval prolongation, which may represent a substrate for ventricular arrhythmias (Class II by the ACC/AHA/NASPE guidelines) Ventricular arrhythmias related to a slow rate or that can be abolished by a more rapid heart rate Ectopic rhythms or other medical conditions are present that require drugs that suppress the automaticity of escape pacemakers and result in symptomatic bradycardia frequently used, but there is divergence of opinion with respect to the necessity of their insertion (Table 5). Some of these conditions reflect advanced but not complete heart block. LONG-TERM PROGNOSIS Complete heart block, as noted, presenting in utero or the neonatal period due to neonatal lupus, is associated with a significant early mortality. Of 175 cases described in two reports, 29 (17%) died either in utero or within the first three months of life. Infants and young children with CHB who are asymptomatic usually remain so until later childhood, adolescence, or adulthood. Children with a mean heart rate below 50 bpm and evidence of an unstable junctional escape rhythm may benefit from early pacemaker implant. One particular risk related to the AV block and the ventricular bradycardia is the development of torsades de pointes (Figure 3). Those patients who do not experience symptoms or syncopal attacks may nonetheless experience physiologic consequences of bradycardia. The ventricular rate tends to fall slowly with age. To compensate for the slow heart rate, the heart enlarges to produce a higher stroke volume; in some cases, this can lead to voltage criteria for left ventricular enlargement and nonspecific ST-T wave changes as well as to heart failure. In general, the prognosis for the majority of young patients following pacemaker implantation for isolated congenital CHB is excellent. However, one report evaluated 16 patients (10 with neonatal lupus) in whom a pacemaker was implanted within the first two weeks of life; 12 developed heart failure before age 24. The major findings on myocardial biopsy were hypertrophy and interstitial fibrosis. During follow-up, four patients died from progressive heart failure and seven required transplantation. In another study of 149 patients followed for 10 years, 6% developed a dilated cardiomyopathy by COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK 179 TABLE 5. Class II Indications Second- or third-degree AV block within the bundle of His in an asymptomatic patient (consider as Class I) Prolonged subsidiary pacemaker recovery time with a pause greater than three seconds Transient surgical second- or third-degree AV block that reverts to bifascicular block Asymptomatic second- or third-degree AV block and a ventricular rate below 50 bpm when awake beyond the first year of life Complete AV block with double or triple rest cycle length pauses or minimal heart rate variability Asymptomatic neonate with congenital CHB and bradycardia in relation to age Long QT syndrome (especially with ventricular arrhythmias) Congenital heart disease and impaired hemodynamics due to sinus bradycardia or loss of AV synchrony Neuromuscular disease with any degree of AV block (including first-degree AV block), with or without symptoms, because there may be unpredictable progression of AV conduction disease 6.5 years of age; risk factors included antiRo/SSA or anti-La/SSB antibodies, increased heart size at initial evaluation, and the absence of improvement with a pacemaker. While the development of heart failure in such patients may be a consequence of myocardial fibrosis associated with CHB, another factor may be the long-term consequences of right ventricular pacing with consequent ventricular asynchrony. Recently, a report compared 23 patients with con- genital CHB, each of whom had a pacemaker, to 30 matched healthy control subjects. Echocardiography was performed before pacemaker implantation and after at least five years of right ventricular pacing in the CHB patients. The CHB patients with pacemakers, not surprisingly when compared to perfectly normal controls, developed asynchronous left ventricular contraction, an increase in left ventricular end-diastolic diameter, a decrease in cardiac output, and a decrease in exercise FIGURE 3. Eight-year-old boy with congenital CHB developed ventricular extrasystoles and torsades de pointes. He spontaneously converted and a dual-chamber pacemaker was implanted. Reprinted with permission from Ho SY et al. The anatomy of congenital heart block. J Am Cardiol 1986;58(3):292–294 and Elsevier. 180 COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK performance. When pacemaker therapy is initially placed in children, there are often limited choices. Biventricular pacing, when the patient is of sufficient size, may, in part, address this observation (Chapter 17). SUGGESTED READING 1. Morquio L. Sur une maladie infantile et familiale characterisée par des modifications permanentes du pouls, des attaques syncopales et epileptiforme et la mort subite. Arch Méd d’Enfants 1901;4:467. 2. White P, Eustis R. Congenital heart block. Am J Dis Child 1921;22:299. 3. Michaelsson M, Engle MA. Congenital complete heart block: An international study of the natural history. Cardiovasc Clin 1972;4:85–101. 4. Johansen AS, Herlin T. Neonatal lupus syndrome. Association with complete congenital atrioventricular block. Ugeskr Laeger 1998;160:2521– 2525. 5. Ross BA. Congenital complete atrioventricular block. Pediatr Clin North Am 1990;37:69–78. 6. Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. J Am Coll Cardiol 2002;39:130– 137. 7. Ho SY, Esscler E, Anderson RH, et al. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol 1986;58:291–294. 8. Anderson RH, Wenick ACG, Losekoot TG, et al. Congenitally complete heart block: Developmental aspects. Circulation 1977;56:90–101. 9. Rosen KM, Mehta A, Rahimtoola SH, et al. Sites of congenital and surgical heart block as defined by His bundle electrocardiography. Circulation 1971;44:833–841. 10. Lev M, Silverman J, Fitzmaurice FM, et al. Lack of connection between the atria and the more peripheral conduction system in congenital atrioventricular block. Am J Cardiol 1971;27:481–490. 11. Lev M, Cuadros H, Paul MH. Interruption of the atrioventricular bundle with congenital atrioventricular block. Circulation 1971;43:703–710. 12. James TN, Spencer MS, Kloepfler JC. De subitaneis mortibus, XXI. Adult onset syncope with comments on the nature of congenital heart block and the morphogenesis of the human atrioventricular septal junction. Circulation 1976;54:1001–1009. 13. Reid JM, Coleman EN, Doig W. Complete congenital heart block. Report of 35 cases. Br Heart J 1982;48:236–239. 14. Nasrallah AT, Gillette PC, Mullins CE. Congenital and surgical atrioventricular block within the His bundle. Am J Cardiol 1975;36:914–920. 15. Buyon JP, Hiebert R, Copel J, et al. Autoimmuneassociated congenital heart block: Demographics, mortality, morbidity and recurrence rates obtained from a National Neonatal Lupus Registry. J Am Coll Cardiol 1998;31:1658–1666. 16. Sholler GF, Walsh EP. Congenital complete heart block in patients without anatomic cardiac defects. Am Heart J 1989;118:1193–1198. 17. Brucato A, Frass, M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001;44:1832–1835. 18. Buyon, JP, Kim, MY, Copel, JA, Friedman, DM. Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient. Arthritis Rheum 2001;44:1723–1727. 19. Alexander E, Buyon JP, Provost TT, et al. Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome: An experimental model. Arthritis Rheum 1992;35:176–189. 20. Miranda-Carus ME, Askanase AD, Clancy RM, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol 2000;165:5345–5351. 21. Garcia S, Nascimento JH, Bonfa E, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA positive patients in rabbit heart. J Clin Invest 1994;93:718– 724. 22. Xiao GQ, Hu K, Boutjdir M. Direct inhibition of expressed cardiac L- and T-type calcium channels by IgG from mothers whose children have congenital heart block. Circulation 2001;103:1599– 1604. 23. Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/RoSSB/La antibodies. Lupus 2002;11:145–151. 24. Cruz RB, Viana VS, Nishioka SA, et al. Is isolated congenital heart block associated to neonatal lupus requiring pacemaker a distinct cardiac syndrome?. Pacing Clin Electrophysiol 2004;27:615–620. 25. Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002;105:843– 848. 26. Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000; 86:236– 239. COMPLETE HEART BLOCK THIRD-DEGREE HEART BLOCK 27. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994;120:544– 551. 28. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med 1987;316:835– 839. 29. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 1995;92:442– 449. 30. Pinsky WW, Gillette PC, Garson A Jr, McNamara DG. Diagnosis, management, and long-term results of patients with congenital complete atrioventricular block. Pediatrics 1982;69:728–733. 31. Karpawich PP, Gillette PC, Garson AJ, et al. Congenital complete atrioventricular block: Clinical and electrophysiologic predictors of need for pacemaker insertion. Am J Cardiol 1981;48:1098– 1102. 32. Gregoratos G, Cheitlin MD, Conill A, et al. ACC/ AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation 1998;97: 1325– 1335. 33. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/NASPE committee to update the 1998 pacemaker guidelines). Circulation 2002;106: 2145–2161. 181 34. Winkler RB, Freed MD, Nadas AS. Exerciseinduced ventricular ectopy in children and young adults with complete heart block. Am Heart J 1980;99:87–92. 35. McHenry MM. Factors influencing longevity in adults with congenital complete heart block. Am J Cardiol 1972;29:416–421. 36. Reybrouck T, Vanden Eynde BB, Dumoulin M, et al. Cardiorespiratory response to exercise in congenital complete atrioventricular block. Am J Cardiol 1989;64:896–899. 37. Kertesz NJ, Friedman RA, Colan SD, et al. Left ventricular mechanics and geometry in patients with congenital complete heart block. Circulation 1997;96:3430–3435. 38. Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: Development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001;37:238–242. 39. Udink ten Cate FE, Breur JM, Cohen MI, et al. Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children. J Am Coll Cardiol 2001;37:1129– 1134. 40. Pordon CM, Moodie DS. Adults with congenital complete heart block: 25-year follow-up. Cleve Clin J Med 1992;59:587–590. 41. Groves AM, Allan LD, Rosenthal E. Outcome of isolated congenital complete heart block diagnosed in utero. Heart 1996;75:190–194. 42. Thambo JB, Bordachar P, Garrigue S, et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 2004;110: 3766–3772. 43. Karpawich PP. Chronic right ventricular pacing and cardiac performance: the pediatric perspective. Pacing Clin Electrophysiol 2004;27(6 Pt 2):844– 849.